Browse CYP1A2

Summary
SymbolCYP1A2
Namecytochrome P450, family 1, subfamily A, polypeptide 2
Aliases P3-450; CP12; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; P450(PA); CYPIA2; P ......
Chromosomal Location15q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane Peripheral membrane protein.
Domain PF00067 Cytochrome P450
Function

Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin.

> Gene Ontology
 
Biological Process GO:0001676 long-chain fatty acid metabolic process
GO:0002237 response to molecule of bacterial origin
GO:0006091 generation of precursor metabolites and energy
GO:0006631 fatty acid metabolic process
GO:0006690 icosanoid metabolic process
GO:0006706 steroid catabolic process
GO:0006720 isoprenoid metabolic process
GO:0006721 terpenoid metabolic process
GO:0006778 porphyrin-containing compound metabolic process
GO:0006805 xenobiotic metabolic process
GO:0008202 steroid metabolic process
GO:0009403 toxin biosynthetic process
GO:0009404 toxin metabolic process
GO:0009410 response to xenobiotic stimulus
GO:0009791 post-embryonic development
GO:0009820 alkaloid metabolic process
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0015980 energy derivation by oxidation of organic compounds
GO:0016042 lipid catabolic process
GO:0016098 monoterpenoid metabolic process
GO:0017144 drug metabolic process
GO:0018894 dibenzo-p-dioxin metabolic process
GO:0019369 arachidonic acid metabolic process
GO:0019373 epoxygenase P450 pathway
GO:0019748 secondary metabolic process
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0032259 methylation
GO:0032355 response to estradiol
GO:0032496 response to lipopolysaccharide
GO:0033013 tetrapyrrole metabolic process
GO:0033559 unsaturated fatty acid metabolic process
GO:0035902 response to immobilization stress
GO:0042493 response to drug
GO:0042737 drug catabolic process
GO:0042738 exogenous drug catabolic process
GO:0042743 hydrogen peroxide metabolic process
GO:0044550 secondary metabolite biosynthetic process
GO:0045333 cellular respiration
GO:0046686 response to cadmium ion
GO:0050665 hydrogen peroxide biosynthetic process
GO:0051186 cofactor metabolic process
GO:0060541 respiratory system development
GO:0070988 demethylation
GO:0070989 oxidative demethylation
GO:0071241 cellular response to inorganic substance
GO:0071248 cellular response to metal ion
GO:0071276 cellular response to cadmium ion
GO:0071466 cellular response to xenobiotic stimulus
GO:0071615 oxidative deethylation
GO:0072593 reactive oxygen species metabolic process
GO:0097267 omega-hydroxylase P450 pathway
GO:1901361 organic cyclic compound catabolic process
GO:1903409 reactive oxygen species biosynthetic process
Molecular Function GO:0004497 monooxygenase activity
GO:0005506 iron ion binding
GO:0009055 electron carrier activity
GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
GO:0016712 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
GO:0016725 oxidoreductase activity, acting on CH or CH2 groups
GO:0019825 oxygen binding
GO:0020037 heme binding
GO:0032451 demethylase activity
GO:0033695 oxidoreductase activity, acting on CH or CH2 groups, quinone or similar compound as acceptor
GO:0034875 caffeine oxidase activity
GO:0046906 tetrapyrrole binding
GO:0070330 aromatase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00140 Steroid hormone biosynthesis
hsa00232 Caffeine metabolism
hsa00380 Tryptophan metabolism
hsa00591 Linoleic acid metabolism
hsa00830 Retinol metabolism
hsa00980 Metabolism of xenobiotics by cytochrome P450
hsa00982 Drug metabolism - cytochrome P450
hsa01100 Metabolic pathways
Reactome R-HSA-5423646: Aflatoxin activation and detoxification
R-HSA-2142753: Arachidonic acid metabolism
R-HSA-211957: Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2
R-HSA-211859: Biological oxidations
R-HSA-211897: Cytochrome P450 - arranged by substrate type
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-156581: Methylation
R-HSA-211945: Phase 1 - Functionalization of compounds
R-HSA-156580: Phase II conjugation
R-HSA-2142816: Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)
R-HSA-2142670: Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)
R-HSA-211981: Xenobiotics
Summary
SymbolCYP1A2
Namecytochrome P450, family 1, subfamily A, polypeptide 2
Aliases P3-450; CP12; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; P450(PA); CYPIA2; P ......
Chromosomal Location15q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CYP1A2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCYP1A2
Namecytochrome P450, family 1, subfamily A, polypeptide 2
Aliases P3-450; CP12; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; P450(PA); CYPIA2; P ......
Chromosomal Location15q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CYP1A2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCYP1A2
Namecytochrome P450, family 1, subfamily A, polypeptide 2
Aliases P3-450; CP12; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; P450(PA); CYPIA2; P ......
Chromosomal Location15q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CYP1A2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4250.29
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0160.982
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.7330.257
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0460.961
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3630.803
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5680.746
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0230.98
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2770.888
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0130.994
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1360.915
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.210.462
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.5090.273
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CYP1A2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCYP1A2
Namecytochrome P450, family 1, subfamily A, polypeptide 2
Aliases P3-450; CP12; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; P450(PA); CYPIA2; P ......
Chromosomal Location15q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CYP1A2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCYP1A2
Namecytochrome P450, family 1, subfamily A, polypeptide 2
Aliases P3-450; CP12; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; P450(PA); CYPIA2; P ......
Chromosomal Location15q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CYP1A2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CYP1A2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCYP1A2
Namecytochrome P450, family 1, subfamily A, polypeptide 2
Aliases P3-450; CP12; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; P450(PA); CYPIA2; P ......
Chromosomal Location15q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CYP1A2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCYP1A2
Namecytochrome P450, family 1, subfamily A, polypeptide 2
Aliases P3-450; CP12; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; P450(PA); CYPIA2; P ......
Chromosomal Location15q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CYP1A2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCYP1A2
Namecytochrome P450, family 1, subfamily A, polypeptide 2
Aliases P3-450; CP12; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; P450(PA); CYPIA2; P ......
Chromosomal Location15q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CYP1A2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCYP1A2
Namecytochrome P450, family 1, subfamily A, polypeptide 2
Aliases P3-450; CP12; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; P450(PA); CYPIA2; P ......
Chromosomal Location15q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CYP1A2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CYP1A2.
ID Name Drug Type Targets #Targets
DB00951IsoniazidSmall MoleculeCYP1A2, CYP2C19, CYP2C8, CYP3A44
DB074532-PHENYL-4H-BENZO[H]CHROMEN-4-ONESmall MoleculeCYP1A21
DB11994DiacereinSmall MoleculeALOX5, CYP1A2, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A43, CYP3A5, CY ......11